tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

UroGen Pharma’s Promising Outlook: Buy Rating Backed by ZUSDURI’s Growth and Strong Financial Health
RatingsUroGen Pharma’s Promising Outlook: Buy Rating Backed by ZUSDURI’s Growth and Strong Financial Health
2d ago
URGN
UroGen Pharma’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
UroGen Pharma’s Earnings Call: Growth Amid Challenges
5d ago
URGN
UroGen Pharma’s ZUSDURI Launch Drives Q3 Growth
PremiumCompany Announcements
UroGen Pharma’s ZUSDURI Launch Drives Q3 Growth
5d ago
URGN
UroGen Pharma files automatic mixed securities shelf
PremiumThe Fly
UroGen Pharma files automatic mixed securities shelf
6d ago
URGN
Urogen Pharma’s Promising Growth and Demand Surge Support Buy Rating
PremiumRatings
Urogen Pharma’s Promising Growth and Demand Surge Support Buy Rating
6d ago
URGN
UroGen Pharma reports Q3 EPS (69c), consensus (68c)
PremiumThe FlyUroGen Pharma reports Q3 EPS (69c), consensus (68c)
6d ago
URGN
UroGen Pharma announces preliminary results from Phase 3 UTOPIA trial
Premium
The Fly
UroGen Pharma announces preliminary results from Phase 3 UTOPIA trial
6d ago
URGN
UroGen Pharma announces CMS assigned permanent HCPCS code for ZUSDURI
Premium
The Fly
UroGen Pharma announces CMS assigned permanent HCPCS code for ZUSDURI
16d ago
URGN
UroGen Pharma announces publication of development program for ZUSDURI
PremiumThe Fly
UroGen Pharma announces publication of development program for ZUSDURI
1M ago
URGN
Promising Developments and Market Potential Drive Buy Rating for Urogen Pharma’s Zusduri
PremiumRatings
Promising Developments and Market Potential Drive Buy Rating for Urogen Pharma’s Zusduri
1M ago
URGN
Citizens JMP healthcare analysts hold an analyst/industry conference call
PremiumThe Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
2M ago
JNJ
CGON
UroGen Pharma announces inducement grants under Nasdaq listing rule
PremiumThe Fly
UroGen Pharma announces inducement grants under Nasdaq listing rule
2M ago
URGN
UroGen Pharma Shareholders Approve Key Proposals at Meeting
PremiumCompany AnnouncementsUroGen Pharma Shareholders Approve Key Proposals at Meeting
3M ago
8K
URGN
Piper starts ‘underestimated’ UroGen Pharma with an Overweight
Premium
The Fly
Piper starts ‘underestimated’ UroGen Pharma with an Overweight
3M ago
URGN
UroGen Pharma initiated with an Overweight at Piper Sandler
Premium
The Fly
UroGen Pharma initiated with an Overweight at Piper Sandler
3M ago
URGN
UroGen Pharma’s Earnings Call: Achievements and Challenges
PremiumCompany Announcements
UroGen Pharma’s Earnings Call: Achievements and Challenges
3M ago
URGN
UroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright
PremiumThe Fly
UroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright
3M ago
URGN
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
PremiumCompany Announcements
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
3M ago
URGN
Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft
PremiumRatings
Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft
3M ago
URGN
UroGen Pharma reports Q2 EPS ($1.05), consensus (83c)
PremiumThe FlyUroGen Pharma reports Q2 EPS ($1.05), consensus (83c)
3M ago
URGN
UroGen Pharma announces 24-month DOR for Phase 3 ENVISION trial
Premium
The Fly
UroGen Pharma announces 24-month DOR for Phase 3 ENVISION trial
3M ago
URGN
UroGen Pharma announces publication of Phase 3b ZUSDURI study results
Premium
The Fly
UroGen Pharma announces publication of Phase 3b ZUSDURI study results
4M ago
URGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >